Bailard’s Dianthus Therapeutics DNTH Stock Holding History

Bailard’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,250	Closed	-$150K	–	576
2020 Q2	$150K	Sell	1,250 -500	-29%	-$70.4K	0.01%	460
2020 Q1	$176K	Buy	1,750 +875	+100%	+$162K	0.01%	413
2019 Q4	$212K	Buy	+875	New	+$164K	0.01%	480

Other funds holding DNTH

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bailard's DNTH Position: Q3 2020 in Review

Bailard sold out of Dianthus Therapeutics (DNTH) in Q3 2020, closing a stake of 1,250 shares — an estimated $150K sold.

Bailard first reported a position in DNTH in Q4 2019 and held it in 3 quarters. The position peaked at $212K in Q4 2019. 94 funds tracked by Wall St. Rank hold DNTH as of Q3 2020.

Bailard reported no remaining Dianthus Therapeutics position as of Q3 2020 after selling out during the quarter.
Bailard sold 1,250 Dianthus Therapeutics shares in Q3 2020, an estimated $150K.
Bailard first reported a position in Dianthus Therapeutics in Q4 2019 and held it in 3 quarters.
Bailard's Dianthus Therapeutics position peaked at $212K in Q4 2019.
94 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2020.

Based on Bailard's 13F filing for Q3 2020, filed 10 Nov 2020.